This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
DexCom (DXCM) Q3 Earnings Beat Estimates, Guidance Revised
by Zacks Equity Research
DexCom's (DXCM) third-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 16.67% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Stocks' Q3 Earnings on Oct 27: LH, BIO & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how LH, BIO, BAX, DXCM and WST are likely to fare this time.
Should You Buy Dexcom (DXCM) Ahead of Earnings?
by Zacks Equity Research
Dexcom (DXCM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat Likely for DexCom (DXCM) This Earnings Season?
by Zacks Equity Research
DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.
Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.
DexCom (DXCM) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
DexCom (DXCM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for Intuitive Surgical (ISRG) in Q3 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) third-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Here's How Much You'd Have If You Invested $1000 in DexCom a Decade Ago
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Company News for Oct 10, 2022
by Zacks Equity Research
Companies In The News Are: LEVI, AMD, DXCM, CANO, CVS.
DexCom (DXCM) Soars 7.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
DexCom (DXCM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
DexCom and Papa John's International have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
DexCom and Papa John's International are part of the Zacks Bull and Bear of the Day article.
Bull of the Day: DexCom, Inc. (DXCM)
by Benjamin Rains
DexCom is a medical device/wearables company focused on helping people monitor and manage their diabetes. DexCom's top-line growth has been stellar and its addressable market is massive considering how widespread diabetes is in the U.S. and elsewhere.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
DexCom (DXCM) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $82, marking a -1.3% move from the previous day.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
DexCom (DXCM) Q2 Earnings Match Estimates, Revenues Miss
by Zacks Equity Research
Despite the top line missing estimates, DexCom's (DXCM) second-quarter results reflected strong domestic and international revenue growth.
DexCom (DXCM) Matches Q2 Earnings Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 0% and 0.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat Likely for DexCom (DXCM) This Earnings Season?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
Avanos Medical (AVNS) to Report Q2 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Factors to Note Ahead of Humana (HUM) Q2 Earnings Release
by Zacks Equity Research
Humana's (HUM) second-quarter results are likely to reflect higher premiums from the Retail segment and overall membership growth, partly offset by elevated technology-linked investments.
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) continues to benefit from a solid product portfolio and a strong international presence. However, supply constraints remain a woe.
Do Options Traders Know Something About DexCom (DXCM) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to DexCom (DXCM) stock based on the movements in the options market lately.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, DexCom (DXCM) closed at $82.19, marking a +1.92% move from the previous day.